LPTX_OUT_1 [2025-04-02 10:49:10 -0400] 3325 Bytes | 895 tokens | Cum: 895 tkns (11.19% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Leap Therapeutics (LPTX) which is at 0.3596 up from 0.2913. So, I pulled together a bunch of data for you to look over real fast. It's still early, 10:49:10 AM on Wed Apr 02, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Leap Therapeutics (LPTX)
IPO: 2014-07-31 (10 Years Ago)
Market Cap: $12,018,339
Shares Outstanding: 41,260,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Here's the first list of news for Leap Therapeutics:

C1 - Mar-31-25 01:42PM - Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript
C2 - Mar-26-25 01:29PM - Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
C3 - Mar-26-25 01:29PM 07:05AM - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
C4 - Mar-26-25 01:29PM 07:00AM - Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
C5 - Jan-28-25 07:00AM - Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
C6 - Jan-06-25 07:00AM - Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
C7 - Nov-26-24 07:00AM - Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
C8 - Nov-13-24 07:00AM - Leap Therapeutics Reports Third Quarter 2024 Financial Results

Prior AI Reports for LPTX:
1. 2025-03-26 – Score: 20 – Target: 0.4500 – Highs: 0.6500 / 0.4236 / 0.35
company-struggles-continues-amidst-persistent-negative-market-performance

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Leap Therapeutics (LPTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

LPTX_OUT_3 [2025-04-02 10:49:18 -0400] 1099 Bytes | 324 tokens | Cum: 1221 tkns (15.26% of 8k)
==========================================================================

Showing C4 (chunk 1 of 9): C4:
**Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study**
Date: Mar-26-25 01:29PM 07:00AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/leap-therapeutics-reports-positive-updated-data-from-sirexatamab-colorectal-cancer-study-302411333.html

Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with highDKK1levels treated with sirexatamab plus bevacizumab and chemotherapy

Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prior anti-VEGF therapy

Leap to host a conference call to present clinical data today,March 26, 2025, at8:00 a.m. ET

CAMBRIDGE, Mass.,March 26, 2025/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LPTX_OUT_5 [2025-04-02 10:49:19 -0400] 968 Bytes | 274 tokens | Cum: 1631 tkns (20.39% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T12:05:52Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Anebulo Pharmaceuticals (NASDAQ:ANEB...
A2 - 2025-03-26T17:29:11Z - Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal C...
A3 - 2025-03-26T17:29:11Z - Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal C...
A4 - 2025-03-26T11:36:03Z - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results...
A5 - 2025-03-26T11:24:05Z - Leap Therapeutics GAAP EPS of -$0.37 misses by $0.01...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

LPTX_OUT_7 [2025-04-02 10:49:20 -0400] 1098 Bytes | 338 tokens | Cum: 1971 tkns (24.64% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's Pre-Market Session - Anebulo Pharmaceuticals (NASDAQ:ANEB), Edap TMS (NASDAQ:EDAP)**Date: 2025-03-27Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44512164/12-health-care-stocks-moving-in-thursdays-pre-market-sessionGainers Soleno Therapeutics SLNO shares increased by 38.8% to $67.98 during Thursday's pre-market session. The company's market cap stands at $2.9 billion. Ocean Biomedical OCEA shares moved upwards by 23.05% to $0.1. The market value of their outstanding shares is at $14.4 million. Edap TMS EDAP shares increased by 20.48% to $2.47. The market value of their outstanding shares is at $91.6 million. As per the press release, Q4 earnings came out today. XTL Biopharmaceuticals XTLB shares moved upwards by 16.36% to $1.28. The company's market cap stands at

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LPTX_OUT_9 [2025-04-02 10:49:27 -0400] 1098 Bytes | 337 tokens | Cum: 2310 tkns (28.88% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): $6.9 million. Regulus Therapeutics RGLS stock rose 16.27% to $1.5. The market value of their outstanding shares is at $99.3 million. Onconetix ONCO stock rose 15.94% to $0.12. The company's market cap stands at $1.7 million. Losers OSR Holdings OSRH stock decreased by 21.9% to $2.96 during Thursday's pre-market session. The market value of their outstanding shares is at $57.0 million. Equillium EQ shares declined by 20.85% to $0.6. The market value of their outstanding shares is at $21.2 million. Petros Pharma PTPI stock fell 11.19% to $0.12. The market value of their outstanding shares is at $3.0 million. HeartSciences HSCS shares fell 10.09% to $2.62. The market value of their outstanding shares is at $2.8 million. Leap Therapeutics LPTX shares declined by 10.04% to $0.41. The company's market cap stands at $15.6 million. The company's, Q4 earnings came out yesterday. Anebulo Pharmace

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LPTX_OUT_11 [2025-04-02 10:49:28 -0400] 1000 Bytes | 314 tokens | Cum: 2794 tkns (34.92% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-03-20T13:35:03Z - Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
B2 - 2023-11-24T17:21:14Z - Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B3 - 2023-11-14T17:00:35Z - Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know
B4 - 2023-06-06T17:04:02Z - Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-05-18T19:25:32Z - 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
B6 - 2023-05-18T17:19:03Z - Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LPTX_OUT_13 [2025-04-02 10:49:31 -0400] 731 Bytes | 205 tokens | Cum: 3001 tkns (37.51% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2243368/heres-why-leap-therapeutics-lptx-is-poised-for-a-turnaround-after-losing--2892-in-4-weeksLeap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LPTX_OUT_15 [2025-04-02 10:49:32 -0400] 1093 Bytes | 274 tokens | Cum: 3352 tkns (41.90% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S8 - 2025-03-26 8-K Item 2.02. Results of Oper and Fin Cond

On March 26, 2025, Leap Therapeutics, Inc. (the Company) announced its financial results for the fourth quarter and year ended December 31, 2024. The full text of the press release issued by the Company in connection with...

S9 - 2025-03-26 8-K Item 2.02. Results of Oper and Fin Cond

On March 26, 2025, Leap Therapeutics, Inc. (the Company) announced its financial results for the fourth quarter and year ended December 31, 2024. The full text of the press release issued by the Company in connection with...

S10 - 2025-03-26 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LPTX_OUT_17 [2025-04-02 10:49:44 -0400] 1098 Bytes | 262 tokens | Cum: 3616 tkns (45.20% of 8k)
==========================================================================

Showing S8 (chunk 1 of 2): S8:
Item 2.02. Results of Operations and Financial Condition

On March 26, 2025, Leap Therapeutics, Inc. (the Company) announced its financial results for the fourth quarter and year ended December 31, 2024. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information set forth under this Item 2.02 and the press release furnished by the Company as Exhibit 99.1 hereto shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LPTX_OUT_19 [2025-04-02 10:49:56 -0400] 16372 Bytes | 4181 tokens | Cum: 7932 tkns (99.15% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+----------------------+
| Volume: 951,635 | Perf Month: -20.40% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 2.58M | Perf Quarter: -88.13% | Short Float: 5.00% | ROE: -141.94% |
+--------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1.81 | Index: - | Short Ratio: 0.60 | ROI: -192.75% |
+--------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 34.11 | Market Cap: 14.30M | Short Interest: 1.54M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.06 | Shs Outstand: 38.33M | Beta: -0.11 | EPS Surprise: 10.84% |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA20: -11.39% | Shs Float: 30.76M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA50: -41.86% | Inst Own: 28.06% | Sales past 5Y: -20.00% | Earnings: Mar 26 BMO |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA200: -83.99% | Insider Own: 25.44% | Employees: 52 | |
+--------------------+-----------------------+-------------------------+----------------------+
| Perf Week: -23.57% | Insider Trans: 0.00% | Debt/Eq: 0.01 | |
+--------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: LEAP THERAPEUTICS, INC. (LPTX) by ONSI DOUGLAS E (CEO,CFO,Pres.,GC,Treas.&Sec.) on 2025-03-28
- Common Stock: 32500 shares at $N/A (D) Footnote: 32,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 32,500 shares of the Company's common stock underlying the January 22 RSUs.
- Restricted Stock Units: 32500 shares at $0 (D) Footnote: 32,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 32,500 shares of the Company's common stock underlying the January 22 RSUs.

Inside Trans: LEAP THERAPEUTICS, INC. (LPTX) by Granfield Christine (VP, Head of Reg Affairs/Qual) on 2025-03-28
- Common Stock: 22500 shares at $N/A (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Common Stock: 6604 shares at $0.3166 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Restricted Stock Units: 22500 shares at $0 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

Inside Trans: LEAP THERAPEUTICS, INC. (LPTX) by Baum Jason (Chief Scientific Officer) on 2025-03-28
- Common Stock: 22500 shares at $N/A (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Common Stock: 6604 shares at $0.3166 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Restricted Stock Units: 22500 shares at $0 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

Inside Trans: LEAP THERAPEUTICS, INC. (LPTX) by LAWLOR AUGUSTINE (Chief Operating Officer) on 2025-03-28
- Common Stock: 22500 shares at $N/A (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Common Stock: 7797 shares at $0.3166 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Restricted Stock Units: 22500 shares at $0 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

Inside Trans: LEAP THERAPEUTICS, INC. (LPTX) by O'Mahony John Mark (Chief Manufacturing Officer) on 2025-03-28
- Common Stock: 22500 shares at $N/A (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.
- Restricted Stock Units: 22500 shares at $0 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.

Inside Trans: LEAP THERAPEUTICS, INC. (LPTX) by Mirabelli Christopher (Chairman of the Board) on 2025-03-28
- Common Stock: 22500 shares at $N/A (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Common Stock: 6672 shares at $0.3166 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- Restricted Stock Units: 22500 shares at $0 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

Inside Trans: LEAP THERAPEUTICS, INC. (LPTX) by Sirard Cynthia (Chief Medical Officer) on 2025-03-28
- Common Stock: 22500 shares at $N/A (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.
- Restricted Stock Units: 22500 shares at $0 (D) Footnote: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -67555000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.3629
Average Volume: 5164211.74
30-Day High: 0.4535
30-Day Low: 0.2913

[Detailed Financials: TTM 2024]
- Total Assets: $49,124,000.0
- Total Liabilities: $14,076,000.0
- Total Equity: $35,048,000.0
- Current Assets: $48,039,000.0
- Current Liabilities: $14,076,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.81

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $279,000

[Detailed Financials: FY 2024]
- Total Assets: $49,124,000.0
- Total Liabilities: $14,076,000.0
- Total Equity: $35,048,000.0
- Current Assets: $48,039,000.0
- Current Liabilities: $14,076,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.81

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $279,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

LPTX_OUT_21 [2025-04-02 10:49:58 -0400] 676 Bytes | 167 tokens | Cum: 8357 tkns (104.46% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

LPTX_IN_23 [2025-04-02 10:49:59 -0400] 126 Bytes | 29 tokens | Cum: 8414 tkns (105.17% of 8k)
==========================================================================

====================================
[2025-04-02 10:49:59] # Analysis Completed
Elapsed Time: 49.02 seconds